Literature DB >> 15527907

Unusual cytogenetic findings in a synovial sarcoma arising in the paranasal sinuses.

Daniela Bettio1, Nicoletta Rizzi, Piergiuseppe Colombo, Paolo Bianchi, Paolo Gaetani.   

Abstract

A fresh specimen from an intracranial tumor, which was histopatologically classified as a synovial sarcoma, was investigated cytogenetically. The direct method failed to give any information due to a lack of mitotic cells after treatment with 70% acetic acid, whereas 6-day cultures showed a 45,XY,del(6q),-10 karyotype. The histologic evaluation was consistent with a synovial sarcoma, which is well characterized from a cytogenetic perspective and involves a t(X;18)(p11;q11) in more than 95% of cases. Reverse-transcription polymerase chain reaction analysis did not show the presence of the SYT-SSX chimeric gene.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15527907     DOI: 10.1016/j.cancergencyto.2004.03.010

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  4 in total

Review 1.  New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull base.

Authors:  Lester D R Thompson; Alessandro Franchi
Journal:  Virchows Arch       Date:  2017-04-25       Impact factor: 4.064

2.  Recurrent primary intracranial synovial sarcoma, a case report and review of the literature.

Authors:  Ataee Kachuee Manizhe; Iman Mohseni; Alireza Sahranavard; Zhale Tabrizi
Journal:  Clin Case Rep       Date:  2022-09-05

3.  Monophasic epithelial synovial sarcoma accompanied by an inverted papilloma in the sphenoid sinus.

Authors:  Xiaohua Jiang; Qi Huang; Jianguo Tang; Matthew R Hoffman
Journal:  Case Rep Med       Date:  2012-12-04

4.  Synovial sarcoma of the maxillary sinus: an extremely rare case with excellent response to chemotherapy.

Authors:  Shin Saito; Hiroyuki Ozawa; Yuuichi Ikari; Nana Nakahara; Fumihiro Ito; Mariko Sekimizu; Junichi Fukada; Kaori Kameyama; Kaoru Ogawa
Journal:  Onco Targets Ther       Date:  2018-01-23       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.